Navigation Links
Xanodyne's New Drug Application for the Treatment of Heavy Menstrual Bleeding (Menorrhagia) Accepted for Filing with a Priority Review Classification
Date:4/2/2009

NEWPORT, Ky., April 2 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted priority review status for its investigational proprietary formulation of tranexamic acid for the treatment of women with menorrhagia, heavy menstrual bleeding (HMB), and its accompanying symptoms. On January 30, 2009, Xanodyne submitted the New Drug Application (NDA) for XP12B, a unique oral therapy which acts as a competitive plasmin inhibitor to prevent fibrinolysis by binding to the lysine receptor sites of plasminogen. This helps to normalize the hyperfibrinolytic activity often present in women with HMB.

"We are pleased with the position that the FDA has taken in granting XP12B a priority review as it reflects their recognition of the important unmet medical need which HMB represents. We look forward to working closely with the agency to further advance this important treatment option to women who suffer from menorrhagia, or heavy menstrual bleeding," said Gary A. Shangold, Chief Medical Officer of Xanodyne.

Under the Prescription Drug User Fee Act (PDUFA), drug products with priority review designation have a 6 month review clock as compared to a 10 month standard review. Upon approval, this product candidate could become the first approved pharmaceutical product in the United States specifically indicated for the treatment of menorrhagia.

About Menorrhagia

HMB, or menorrhagia, represents a frequent and significant medical condition encountered by obstetricians, gynecologists and primary care physicians. Menorrhagia has been described as regular, normal intervals of menstruation with excessive volume that may exceed 80 milliliters of blood loss per menstrual cycle. At present, no pharmacotherapy has ever been approved by the FDA for the treatment of this disorder.

About Xanodyne

Xanodyne Pharmaceuticals, Inc., which commenced operations in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. Xanodyne markets a portfolio of revenue generating products consisting of pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas.


'/>"/>
SOURCE Xanodyne Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Upcoming Symposium to Bridge the Gap between Osteoporosis Research and its Applications to Clinical Practice with Focus on Secondary Osteoporosis, Osteoporosis in Men, and Lessons from Space Travel for Improving Bone Health
2. Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers
3. GlobalMedia Provides Free Grant Writing and Application Assistance to Healthcare Providers and Professionals Seeking Their Share of Billions in Economic Stimulus Dollars
4. CareTech Solutions Launches Robust Service Desk Solution to Support Clinical Applications and Technology within Continuum Health Partners Hospitals
5. Hollow gold nanospheres show promise for biomedical and other applications
6. Call for Presentations: Applications of High-Power Semiconductor Lasers Conference & Exhibit
7. FDA Clears Cellectars IND Application for Lead Drug Candidate
8. FDA Halts New Applications From Indian Drug Makers Plant
9. CUREXO Technology Corporation Announces 510(k) Submission to FDA for Total Knee Arthroplasty Application
10. Nephros Provides Update on 510k Applications
11. IMRIS announces development program for MR guided radiation and interventional applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Chronic stress can have a silent, yet ... weaken the immune system and increase inflammation, both of which raise the risk of ... congenital heart disease program at Harvard-affiliated Massachusetts General Hospital. Chronic stress also can lead ...
(Date:5/5/2016)... Texas (PRWEB) , ... May 05, 2016 , ... ... relationship-marketing firm, honored finalists and winners Tuesday evening, May 3, at the 2016 ... Texas. , Scott Pettigrew, Vice President and Chief Security Officer of HMS, ...
(Date:5/5/2016)... ... 2016 , ... If you don’t mind a bit of prickly therapy to ... to consider a treatment that some have called the next great tool in dermatology ... also known as skin needling, is a procedure using a device covered with tiny, ...
(Date:5/5/2016)... ... 05, 2016 , ... Pigment Laser Tattoo Removal Center is proud to be ... PiQo4™ laser, the first 4-wavelenth picosecond laser to receive FDA Clearance. This new ... on the market. Jeremy Miller, Tattoo Artist and former reality show contestant on ...
(Date:5/5/2016)... ... May 05, 2016 , ... Liposuction specialist Marcia V. Byrd, MD spoke ... Missouri at the Marriot St. Louis Airport Hotel. This year’s conference was titled “Living ... conference about her unique specialization in treating Lipedema. Dr. Byrd is considered one of ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 4, 2016 Research ... "Global Cancer Stem Cell Therapy Market Outlook 2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has improved significantly ... expected to be developed in coming years. Many cancer ... Cancer stem cell therapies are also expected to be ...
(Date:5/3/2016)... , May 3, 2016   BIOTRONIK ... technology, today announced Food and Drug Administration (FDA) ... defibrillator that provides heart failure patients with access ... devices also have remote monitoring with daily automatic ... the heart rate in response to physiological demands. ...
(Date:5/3/2016)... Pharmaceutical giant Johnson & Johnson has been ... says its talc-based powder products caused ovarian cancer. The ... million in compensatory damages and $50 million in punitive ... , This is the second in a ... same court awarded $72 million to the family of ...
Breaking Medicine Technology: